Ekso Bionics Holdings, Inc. Common Stock (CHRN) Stock Competitors & Peer Comparison
See (CHRN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Specialties Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHRN | $22.23 | -1.24% | 79.2M | -14.25 | -$1.56 | N/A |
| ALC | $67.80 | -0.48% | 33.1B | 21.33 | $3.18 | +0.53% |
| PHG | $27.10 | -0.70% | 26.3B | 15.49 | $1.75 | +3.66% |
| STE | $215.67 | +2.41% | 21B | 21.21 | $10.17 | +1.17% |
| BRKRP | $451.04 | +0.35% | 9.3B | 888.96 | $0.51 | +0.33% |
| DRTSW | $2.10 | -8.30% | 1B | -3.25 | -$0.65 | N/A |
| MOBI | $14.63 | +12.45% | 486.4M | -0.78 | -$18.78 | N/A |
| SI | $22.79 | +5.46% | 470.3M | -0.34 | -$65.74 | N/A |
| CV | $7.52 | +7.58% | 375.7M | -3.01 | -$2.50 | N/A |
| MASS | $8.78 | -2.23% | 332M | -14.63 | -$0.60 | N/A |
Stock Comparison
CHRN vs ALC Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, ALC has a market cap of 33.1B. Regarding current trading prices, CHRN is priced at $22.23, while ALC trades at $67.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas ALC's P/E ratio is 21.33. In terms of profitability, CHRN's ROE is N/A, compared to ALC's ROE of +0.04%. Regarding short-term risk, CHRN is more volatile compared to ALC. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check ALC's competition here
CHRN vs PHG Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, PHG has a market cap of 26.3B. Regarding current trading prices, CHRN is priced at $22.23, while PHG trades at $27.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas PHG's P/E ratio is 15.49. In terms of profitability, CHRN's ROE is N/A, compared to PHG's ROE of +0.09%. Regarding short-term risk, CHRN is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check PHG's competition here
CHRN vs STE Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, STE has a market cap of 21B. Regarding current trading prices, CHRN is priced at $22.23, while STE trades at $215.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas STE's P/E ratio is 21.21. In terms of profitability, CHRN's ROE is N/A, compared to STE's ROE of +0.11%. Regarding short-term risk, CHRN is more volatile compared to STE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check STE's competition here
CHRN vs BRKRP Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, BRKRP has a market cap of 9.3B. Regarding current trading prices, CHRN is priced at $22.23, while BRKRP trades at $451.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas BRKRP's P/E ratio is 888.96. In terms of profitability, CHRN's ROE is N/A, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, CHRN is more volatile compared to BRKRP. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check BRKRP's competition here
CHRN vs DRTSW Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, DRTSW has a market cap of 1B. Regarding current trading prices, CHRN is priced at $22.23, while DRTSW trades at $2.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas DRTSW's P/E ratio is -3.25. In terms of profitability, CHRN's ROE is N/A, compared to DRTSW's ROE of -0.73%. Regarding short-term risk, CHRN is more volatile compared to DRTSW. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check DRTSW's competition here
CHRN vs MOBI Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, MOBI has a market cap of 486.4M. Regarding current trading prices, CHRN is priced at $22.23, while MOBI trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas MOBI's P/E ratio is -0.78. In terms of profitability, CHRN's ROE is N/A, compared to MOBI's ROE of +0.31%. Regarding short-term risk, CHRN is more volatile compared to MOBI. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check MOBI's competition here
CHRN vs SI Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, SI has a market cap of 470.3M. Regarding current trading prices, CHRN is priced at $22.23, while SI trades at $22.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas SI's P/E ratio is -0.34. In terms of profitability, CHRN's ROE is N/A, compared to SI's ROE of -0.35%. Regarding short-term risk, CHRN is more volatile compared to SI. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check SI's competition here
CHRN vs CV Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, CV has a market cap of 375.7M. Regarding current trading prices, CHRN is priced at $22.23, while CV trades at $7.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas CV's P/E ratio is -3.01. In terms of profitability, CHRN's ROE is N/A, compared to CV's ROE of +1.27%. Regarding short-term risk, CHRN is more volatile compared to CV. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check CV's competition here
CHRN vs MASS Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, MASS has a market cap of 332M. Regarding current trading prices, CHRN is priced at $22.23, while MASS trades at $8.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas MASS's P/E ratio is -14.63. In terms of profitability, CHRN's ROE is N/A, compared to MASS's ROE of -0.26%. Regarding short-term risk, CHRN is more volatile compared to MASS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check MASS's competition here
CHRN vs APYX Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, APYX has a market cap of 188.4M. Regarding current trading prices, CHRN is priced at $22.23, while APYX trades at $4.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas APYX's P/E ratio is -20.45. In terms of profitability, CHRN's ROE is N/A, compared to APYX's ROE of -0.91%. Regarding short-term risk, CHRN is more volatile compared to APYX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check APYX's competition here
CHRN vs EDAP Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, CHRN is priced at $22.23, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas EDAP's P/E ratio is -5.80. In terms of profitability, CHRN's ROE is N/A, compared to EDAP's ROE of -1.49%. Regarding short-term risk, CHRN is more volatile compared to EDAP. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check EDAP's competition here
CHRN vs HYPR Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, HYPR has a market cap of 123.8M. Regarding current trading prices, CHRN is priced at $22.23, while HYPR trades at $1.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas HYPR's P/E ratio is -3.67. In terms of profitability, CHRN's ROE is N/A, compared to HYPR's ROE of -1.01%. Regarding short-term risk, CHRN is less volatile compared to HYPR. This indicates potentially lower risk in terms of short-term price fluctuations for CHRN.Check HYPR's competition here
CHRN vs NYXH Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, NYXH has a market cap of 66.1M. Regarding current trading prices, CHRN is priced at $22.23, while NYXH trades at $1.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas NYXH's P/E ratio is -0.67. In terms of profitability, CHRN's ROE is N/A, compared to NYXH's ROE of -1.64%. Regarding short-term risk, CHRN is more volatile compared to NYXH. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check NYXH's competition here
CHRN vs MDAI Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, MDAI has a market cap of 54.4M. Regarding current trading prices, CHRN is priced at $22.23, while MDAI trades at $1.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas MDAI's P/E ratio is -3.80. In terms of profitability, CHRN's ROE is N/A, compared to MDAI's ROE of +1.79%. Regarding short-term risk, CHRN is more volatile compared to MDAI. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check MDAI's competition here
CHRN vs QTEXW Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, QTEXW has a market cap of 10.1M. Regarding current trading prices, CHRN is priced at $22.23, while QTEXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas QTEXW's P/E ratio is -0.14. In terms of profitability, CHRN's ROE is N/A, compared to QTEXW's ROE of N/A. Regarding short-term risk, CHRN is less volatile compared to QTEXW. This indicates potentially lower risk in terms of short-term price fluctuations for CHRN.Check QTEXW's competition here
CHRN vs WOK Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, WOK has a market cap of 5.4M. Regarding current trading prices, CHRN is priced at $22.23, while WOK trades at $2.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas WOK's P/E ratio is N/A. In terms of profitability, CHRN's ROE is N/A, compared to WOK's ROE of -0.07%. Regarding short-term risk, CHRN is more volatile compared to WOK. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check WOK's competition here
CHRN vs BIAFW Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, BIAFW has a market cap of 3.8M. Regarding current trading prices, CHRN is priced at $22.23, while BIAFW trades at $0.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas BIAFW's P/E ratio is N/A. In terms of profitability, CHRN's ROE is N/A, compared to BIAFW's ROE of -3.59%. Regarding short-term risk, CHRN is more volatile compared to BIAFW. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check BIAFW's competition here
CHRN vs ITOC Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, ITOC has a market cap of 2.9M. Regarding current trading prices, CHRN is priced at $22.23, while ITOC trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas ITOC's P/E ratio is -0.99. In terms of profitability, CHRN's ROE is N/A, compared to ITOC's ROE of -0.44%. Regarding short-term risk, CHRN is more volatile compared to ITOC. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check ITOC's competition here
CHRN vs FEED Comparison June 2026
CHRN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRN stands at 79.2M. In comparison, FEED has a market cap of 633.9K. Regarding current trading prices, CHRN is priced at $22.23, while FEED trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRN currently has a P/E ratio of -14.25, whereas FEED's P/E ratio is -0.01. In terms of profitability, CHRN's ROE is N/A, compared to FEED's ROE of -0.44%. Regarding short-term risk, CHRN is more volatile compared to FEED. This indicates potentially higher risk in terms of short-term price fluctuations for CHRN.Check FEED's competition here